- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00595205
Intussusception Surveillance After Rotarix Introduction in Mexico
Post-Authorization Safety Study (PASS) of Post-Marketing Surveillance for Intussusception Following Rotarix™ Introduction Into the Instituto Mexicano Del Seguro Social (IMSS) in Mexico
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale for amendment 3:
The findings from the first year of the implementation of the active surveillance showed that most Lower Respiratory Tract-Related Post-Neonatal (LRTI) Mortality cases could not be included into the study, because most of the grieving parents refused to participate in the study. The European Medicines Agency Marketing Authorization Holders (EMEA MAH) also generated a substantial amount of additional clinical and post-marketing safety data throughout the world, which clearly indicated the absence of any safety signal when considering the LTRI-related fatalities. Therefore surveillance for LRTI mortality cases was removed from the study design. The number of sites was reduced from approximately 230 to about 60 to 90 in order to reflect the above mentioned change that reduced the need for so many sites. Additionally, passive surveillance for IS cases through the IMSS database was not feasible, due to restrictions of the IMSS internal policies and to the current limitations in the databases linkage and structure abilities.
Lastly, SAEs reporting procedures had to be adjusted according to the Council for International Organizations of Medical Sciences (CIOMS) Working Group V, 2001 publication such that there will be no expedited safety reporting for this study.
Design This is a post marketing ,Phase IV, observational, prospective, self-controlled case series, vaccine safety study including: a) hospital-based surveillance to monitor for the occurrence of IS through active surveillance; b) a self-controlled case series (SCCS) design/analysis to assess the temporal association with Rotarix™ of the IS ascertained through active surveillance.
The aim of the active hospital-based surveillance system is to identify all definite IS cases in children younger than one year of age (children ineligible on day of first birthday) among IMSS members. Surveillance will be conducted in approximately 60 to 90 IMSS health facilities with pediatric surgery service.
Study participation for children fitting the surveillance case definition of IS will include parental/guardian/legal representative interview, as well as a review of medical charts and vaccination records. Additional medical information will be collected through medical record review during hospitalization and after the child has been discharged.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Mexico Df, Mexico, 06720
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
A child's clinical episode will be defined as an IS case and deemed eligible for the study if he/she meets the following criteria:
- Subject is an IMSS affiliate
- Subject is being treated/has been treated/has been referred for treatment at one of the IMSS hospitals/medical facilities with IS during the study period.
- Male or female child is <one year of age at the time of diagnosis of the IS (child becomes ineligible on the day of their first birthday)
- Subject is diagnosed with definite IS based on the Brighton criteria
- Written informed consent is obtained from the parent/guardian/legal representative of the subject Subjects meeting the above criteria will be eligible for inclusion in this study regardless of whether or not the subject has had a radiographically or surgically confirmed case of IS prior to the current episode.
Exclusion Criteria:
Not applicable
Study Plan
How is the study designed?
Design Details
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group IS
Subjects <1 year of age with definite intussusception cases who had received Rotarix™.
|
Reviewing of the hospital log to monitor for the occurrence of intussusception.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Occurrence of definite IS episodes within Day 0 to Day 30 following vaccination
Time Frame: 0- 30 days following Rotarix vaccination
|
0- 30 days following Rotarix vaccination
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Occurrence of definite IS episodes within Day 0 to Day 15 following vaccination
Time Frame: Day 0 to Day 15 post Rotarix vaccination
|
Day 0 to Day 15 post Rotarix vaccination
|
Yearly occurrence of definite IS episodes (regardless of vaccination status)
Time Frame: Assessed for the interim analysis and after study conclusion
|
Assessed for the interim analysis and after study conclusion
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Velázquez FR et al. Postmarketing surveillance to assess risk of intussusception following introduction of the G1P[8] human rotavirus vaccine in Mexico. Abstract presented at the Excellence in Paediatrics (EXPE). London, UK, 2-4 December 2010.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 104435
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rotavirus Vaccines
-
Taipei Medical University Shuang Ho HospitalUnknownRotavirus VaccinesTaiwan
-
Seattle Children's HospitalNational Center for Research Resources (NCRR); Thrasher Research FundCompletedIntestinal Failure | Rotavirus VaccinesUnited States
-
GlaxoSmithKlineCompletedRotavirus Infection | Rotavirus VaccinesUnited States
-
GlaxoSmithKlineCompletedInfections, Rotavirus | Rotavirus VaccinesUnited States, Finland, Germany, Taiwan, Spain, Costa Rica, Korea, Republic of, Japan
-
GlaxoSmithKlineCompletedInfections, Rotavirus | Rotavirus VaccinesJapan
-
GlaxoSmithKlineCompletedInfections, Rotavirus | Rotavirus VaccinesKorea, Republic of
-
GlaxoSmithKlineCompletedInfections, Rotavirus | Rotavirus VaccinesPhilippines
-
Limited Liability Company Pharm AidCompletedRotavirus Infections | Rotavirus VaccinesRussian Federation
-
GlaxoSmithKlineCompletedInfections, Rotavirus | Rotavirus VaccinesPhilippines
-
GlaxoSmithKlineCompletedInfections, Rotavirus | Rotavirus VaccinesBelgium
Clinical Trials on Hospital log review.
-
Uppsala University HospitalUppsala UniversityCompleted
-
Zealand University HospitalNykøbing Falster County Hospital; Region Zealand; Lolland Municipality; Guldborgsund... and other collaboratorsCompletedReadmission | Discharge Planning | Hospital | Frail Elderly PatientsDenmark
-
Oslo Metropolitan UniversityThe Norwegian Directorate for Education and TrainingCompletedInterprofessional Team CollaborationNorway
-
University of Alabama at BirminghamCompletedAdherence, Medication | Pediatric ALL | Functional Constipation | Survey, Family LifeUnited States
-
Duke UniversityTerminated
-
University of LeicesterCompletedPain, AcuteUnited Kingdom
-
Makerere UniversityUniversity of Michigan; Michigan State UniversityCompleted
-
Cairo UniversityNot yet recruiting
-
Brigham and Women's HospitalAbbottCompleted
-
Memorial Sloan Kettering Cancer CenterNew York University; The City College of New York; New York State Department...CompletedVehicular EnvironmentUnited States